Price Alert

Charles River Laboratorie... (CRL)

NYSE: CRL · Real-Time Price · USD

156.64

0.84 (0.54%)

At close: Aug 15, 2025, 3:59 PM

156.68

0.03%

After-hours: Aug 15, 2025, 05:29 PM EDT

0.54% (1D)

Bid	150
Market Cap	7.71B
Revenue (ttm)	4.03B
Net Income (ttm)	-69.22M
EPS (ttm)	-1.29
PE Ratio (ttm)	-121.43
Forward PE	14.12
Analyst	Hold

Ask	168.88
Volume	431,365
Avg. Volume (20D)	900,854
Open	156.72
Previous Close	155.80
Day's Range	156.45 - 158.16
52-Week Range	91.86 - 230.02
Beta	1.48

About CRL

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CRL

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CRL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Charles River Laboratories International has released their quartely earnings on Aug 6, 2025:

Revenue of $1.03B exceeds estimates by $47.9M, with 0.59% YoY growth.

EPS of 3.12 exceeds estimates by 0.62, with 11.43% YoY growth.

Next Earnings Release

Charles River Laboratories International Inc. is scheduled to release its earnings on Nov 5, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

-10.25%

CRL stock has given up its prior gain. Charles Riv... Unlock content with Pro Subscription

1 week ago

-10.25%

Charles River shares are trading higher after the company reported better-than-expected Q2 adjusted EPS and sales.

News

4 days ago · zacks.com

Interpreting Charles River (CRL) International Revenue Trends

Review Charles River's (CRL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

1 week ago · seekingalpha.com

Charles River Laboratories International, Inc. (CRL) Q2 2025 Earnings Call Transcript

Charles River Laboratories International, Inc. (NYSE:CRL ) Q2 2025 Earnings Conference Call August 6, 2025 9:00 AM ET Company Participants Flavia H. Pease - Corporate Executive VP & CFO James C.

1 week ago · benzinga.com

Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing

Charles River Laboratories International Inc. CRL stock is trading lower on Wednesday after the company released second-quarter 2025 earnings.

1 week ago · seekingalpha.com

Charles River: Margin Fears Outweigh Solid Q2

Charles River Laboratories posted a strong Q2 beat, but results were boosted by one-time items and cost cuts that may not be sustainable. Ongoing risks include regulatory pressure to phase out animal ...

1 week ago · zacks.com

Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Str...

1 week ago · zacks.com

CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View

Charles River shares jump 9.3% pre-market after Q2 earnings and revenues beat estimates. The company raises its 2025 outlook.

1 week ago · zacks.com

Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates

Charles River Laboratories (CRL) came out with quarterly earnings of $3.12 per share, beating the Zacks Consensus Estimate of $2.5 per share. This compares to earnings of $2.8 per share a year ago.

1 week ago · reuters.com

Charles River raises profit forecast on growing demand for drug development services

Charles River Laboratories on Wednesday raised its annual profit forecast, betting on growing demand for its drug discovery and development services from drugmakers, sending its shares up more than 4%...

1 week ago · businesswire.com

Charles River Laboratories Announces Second-Quarter 2025 Results

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Second-Quarter 2025 Results.

2 weeks ago · zacks.com

Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Load More News